Compared to participants without NAFLD, participants with NAFLD had a higher prevalence of metabolic disorders including diabetes, obesity, hypertension, and dyscholestrolemia; more elevated hepatic inflammatory markers including ferritin, CRP, AST, ALT, and GGT; higher RBC counts; and RDW and lower dietary folate. The gene discussed is GPT; the disease is Obesity.